Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

MA Dimopoulos, J Hillengass, S Usmani, E Zamagni, S Lentzsch, FE Davies, N Raje, O Sezer, S Zweegman, J Shah, A Badros, K Shimizu, P Moreau, CS Chim, JJ Lahuerta, J Hou, A Jurczyszyn, H Goldschmidt, Pieter Sonneveld, A PalumboH Ludwig, M Cavo, B Barlogie, K Anderson, GD Roodman, SV Rajkumar, BGM Durie, E Terpos

Research output: Contribution to journalArticleAcademicpeer-review

252 Citations (Scopus)


Purpose The aim of International Myeloma Working Group was to develop practical recommendations for the use of magnetic resonance imaging (MRI) in multiple myeloma (MM). Methods An interdisciplinary panel of clinical experts on MM and myeloma bone disease developed recommendations for the value of MRI based on data published through March 2014. Recommendations MRI has high sensitivity for the early detection of marrow infiltration by myeloma cells compared with other radiographic methods. Thus, MRI detects bone involvement in patients with myeloma much earlier than the myeloma-related bone destruction, with no radiation exposure. It is the gold standard for the imaging of axial skeleton, for the evaluation of painful lesions, and for distinguishing benign versus malignant osteoporotic vertebral fractures. MRI has the ability to detect spinal cord or nerve compression and presence of soft tissue masses, and it is recommended for the workup of solitary bone plasmacytoma. Regarding smoldering or asymptomatic myeloma, all patients should undergo whole-body MRI (WB-MRI; or spine and pelvic MRI if WB-MRI is not available), and if they have > one focal lesion of a diameter > 5 mm, they should be considered to have symptomatic disease that requires therapy. In cases of equivocal small lesions, a second MRI should be performed after 3 to 6 months, and if there is progression on MRI, the patient should be treated as having symptomatic myeloma. MRI at diagnosis of symptomatic patients and after treatment (mainly after autologous stem-cell transplantation) provides prognostic information; however, to date, this does not change treatment selection. (C) 2015 by American Society of Clinical Oncology
Original languageUndefined/Unknown
Pages (from-to)657-U186
JournalJournal of Clinical Oncology
Issue number6
Publication statusPublished - 2015

Cite this